Tom Hulick, CEO of Strategy Asset Managers, sat down with CNBC’s Power Lunch to discuss the GLP-1 weight loss space following Viking Therapeutics’ positive trial data, and why Eli Lilly is currently one of his firm’s top holdings. In his view, the GLP-1 sector may still have room to grow, and he pointed to the shift from injections to oral pills as a potential next phase of development for Lilly.
Beyond Lilly, Tom discussed Johnson & Johnson as another pharma name the firm holds. He noted that upcoming patent cliffs are pushing the industry to invest in next-generation drugs in areas like cancer and neurology, which he believes could create opportunities across pharma and biotech in the years ahead.
On the AI front, Tom discussed Meta’s new consumer agent app, Muse, which he sees as a potential revenue opportunity for Meta. He views personal AI assistants as one way consumers are engaging with the broader AI ecosystem.